Fertility and sterility · 2008
Significant elevation of plasma matrix metalloproteinase-9 level and its ratio to matrix metalloproteinase-2 in patients with pelvic inflammatory disease.
Оценочное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Po-Hui, Tsai Hsiu-Ting, Tee Yi-Torng, Lin Long-Yau, Yang Shun-Fa, Hsieh Yih-Shou
Аннотация
OBJECTIVE: To detect the expression of plasma matrix metalloproteinase-2 (MMP-2) and MMP-9, and MMP-9:MMP-2 ratio in patients with pelvic inflammatory disease (PID).
DESIGN: A consecutive study with approximate 1:2 case-to-control ratio.
SETTING: University hospital.
PATIENT(S): Forty-seven patients with PID and 80 healthy women.
INTERVENTION(S): Collected blood specimens of patients with PID before and after treatment.
MAIN OUTCOME MEASURE(S): ELISA and gelatin zymography were used to measure the expression of plasma MMP-2 and MMP-9.
RESULT(S): The level of plasma MMP-9 or MMP-9:MMP-2 ratio was elevated in patients with PID compared with healthy controls and decreased significantly after treatment. The activity of MMP-9, but not MMP-2, tended to be higher in 47 patients with PID before the treatment compared with that after the treatment. Pretreatment plasma MMP-9 or MMP-9:MMP-2 ratio was significantly correlated with white blood cell (WBC) and neutrophil counts. As prediction markers for PID, the sensitivities of MMP-9 and MMP-9:MMP-2 ratio were 76.6% and 76.6%, whereas the negative predictive values were 82.5% and 83.3%.
CONCLUSION(S): Level of plasma MMP-9 and MMP-9:MMP-2 ratio may act as prediction markers for PID. In patients with PID, 80% have a plasma MMP-9 level higher than 115 ng/mL or a MMP-9:MMP-2 ratio higher than 2.15.
DESIGN: A consecutive study with approximate 1:2 case-to-control ratio.
SETTING: University hospital.
PATIENT(S): Forty-seven patients with PID and 80 healthy women.
INTERVENTION(S): Collected blood specimens of patients with PID before and after treatment.
MAIN OUTCOME MEASURE(S): ELISA and gelatin zymography were used to measure the expression of plasma MMP-2 and MMP-9.
RESULT(S): The level of plasma MMP-9 or MMP-9:MMP-2 ratio was elevated in patients with PID compared with healthy controls and decreased significantly after treatment. The activity of MMP-9, but not MMP-2, tended to be higher in 47 patients with PID before the treatment compared with that after the treatment. Pretreatment plasma MMP-9 or MMP-9:MMP-2 ratio was significantly correlated with white blood cell (WBC) and neutrophil counts. As prediction markers for PID, the sensitivities of MMP-9 and MMP-9:MMP-2 ratio were 76.6% and 76.6%, whereas the negative predictive values were 82.5% and 83.3%.
CONCLUSION(S): Level of plasma MMP-9 and MMP-9:MMP-2 ratio may act as prediction markers for PID. In patients with PID, 80% have a plasma MMP-9 level higher than 115 ng/mL or a MMP-9:MMP-2 ratio higher than 2.15.